Darifenacin
Darifenacin Hydrobromide
- Strength
- 7.5 mg/1
- Form
- Tablet, Extended Release
- Class
- Cholinergic Muscarinic Antagonist
Cipla USA Inc.
Listed by Aurobindo Pharma Limited
| Dosage form | Tablet, Film Coated, Extended Release |
|---|---|
| Route | Oral |
| Drug class | Cholinergic Muscarinic Antagonist |
| Approval route | ANDA — approved generic |
| NDC code | 65862-862 |
| FDA application | ANDA206743 |
| RxNorm concept | 485421 |
| Package sizes listed | 4 |
| Marketed since | September 2016 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Darifenacin Hydrobromide
Cipla USA Inc.
Torrent Pharmaceuticals Limited
Alembic Pharmaceuticals Limited
Macleods Pharmaceuticals Limited
Darifenacin Hydrobromide
POLYGEN PHARMACEUTICALS INC.
Darifenacin Hydrobromide
Cipla USA Inc.
Bryant Ranch Prepack
Aurobindo Pharma Limited
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.